Commercial Excellence in Pharma: The Four Domains

Commercial excellence in pharma is the discipline of making the commercial system perform as well as the science it carries. Institutions tend to industrialize whatever they can name, and they leave unnamed work to whoever happens to be standing closest. In practice the discipline has been built as four domains, three of them long established and named, and a fourth that is now being named. The first three are launch excellence, marketing excellence and sales excellence. The fourth is Customer Excellence.

Most writing on this question stops at that list. The category deserves better treatment, because each of the three established domains carries a real body of practice, a real budget and people who have spent whole careers inside it. Understanding precisely what each one owns is the only honest way to see what none of them owns.

What launch excellence owns

Launch excellence secures early momentum in the window where a brand's long run trajectory is set. Its work is cross functional readiness ahead of approval, orchestration across medical, marketing, access and field, and speed from first prescription to peak. It sequences a very large number of dependencies against a fixed date, which is organizational discipline of a kind few other functions are asked to demonstrate. Of the four domains it is the most mature and usually the best resourced.

The reason for that maturity is sound. A brand's early trajectory tends to predict its lifetime trajectory, so the industry concentrated its sharpest operating discipline in the period where stakes compound fastest. Launch excellence is treated with more rigor than any other commercial domain because the evidence justified treating it that way. Anyone writing about the subject should say that before saying anything else.

What marketing excellence owns

Marketing excellence shapes how a medicine is understood. It governs narrative, evidence generation, segmentation and message discipline, which together determine whether a clinician meets the science in a form they can act on. Done well it converts clinical data into clinical conviction, then holds that conviction consistent across every channel a physician touches. Its instruments are among the most refined anywhere in the industry.

Message discipline in particular is harder than it looks from outside. A claim has to survive regulatory review, stay true to the label, remain legible to a specialist and still differentiate against comparators that may be clinically similar. Marketing excellence carries that burden continuously rather than at launch alone. It is rarely given credit for how much judgment the work actually requires.

What sales excellence owns

Sales excellence sustains presence and relationship capital in the clinical community. Its work runs through territory design, reach, frequency and call planning, and through the accumulated trust that lets a representative be useful rather than merely present. No channel in pharma carries more brand defining weight, and none costs more to operate.

Questions of field force effectiveness are usually framed as questions of efficiency. The more useful question is what the field is in a position to observe. A representative sitting in an office often sees a barrier forming months before any dashboard registers it. Sales excellence built the discipline of being there, which is the harder half. What it was never asked to build is the discipline of acting on what being there reveals.

The boundary condition the three domains share

Each of the three optimizes performance within a category that already exists. Each is accountable for creating clinical intent, and each is measured on how much of that intent forms and how quickly. Not one of them owns whether the intent survives the journey from decision to sustained therapy. That is a design gap rather than a failure of any discipline, which matters because the two call for entirely different remedies.

A launch can hit every readiness and uptake target while a meaningful share of first prescriptions never becomes a filled prescription. A campaign can achieve conviction while a prior authorization stalls. A field organization can hold strong relationships while patients fall out of therapy in the third quarter. None of those outcomes indicts the domain that produced them, because no domain was ever handed the mandate.

The gap is visible in what customers report about engagement they already receive. Deloitte 2025 research found only 28 percent of HCPs believe pharma's engagement strategies meet their needs, against 82 percent of life sciences executives who say they are satisfied with those same strategies. Three mature domains produced that spread while each performed its own job competently. A system can be excellent in every part and still be experienced as incoherent by the person moving through it.

What is the fourth domain the industry is now naming?

Customer Excellence is the fourth domain. It is the enterprise capability that designs, delivers and scales coherent experiences across the three paths a customer travels, and that governs whether clinical intent becomes realized therapy. Those paths are the Path to Prescribe, the Path to Fulfill and the Path to Adhere. Intent created on the first can be lost on either of the other two, and often is.

Customer Excellence is CX 3.0, Fit-for-Pharma, a pharma specific interpretation rather than a method imported from retail or hospitality. The full case for treating it as a domain, including why earlier imported versions were rationally rejected, sits in a separate piece on the fourth pillar of commercial excellence. I will not re-argue it here. What belongs on this page is what the category looks like once the fourth domain is standing in it.

What separates a real function from a reporting one

Any commercial excellence function can be tested in about ten minutes. A real one carries five markers: a named discipline, an owner, a measure, a body of practice and a budget line. Anything with fewer than all five is an initiative, however senior its sponsor and however good its intentions. Initiatives produce decks, while functions produce decisions.

The marker that falls off most often is the budget line. A discipline without its own money depends on whoever does have money, which means it negotiates for attention rather than setting standards. The owner marker fails nearly as frequently, usually because accountability has been distributed across a steering committee. Shared accountability with no single name on it tends to behave like no accountability at all.

The body of practice marker is the slowest to earn and the easiest to imitate. It means documented methods, trained practitioners and some reliable way to tell competent work from incompetent work. Launch, marketing and sales excellence each cleared that bar over decades. A function claiming a place beside them should expect to be judged against the same standard.

The measures the function should carry

Commercial excellence becomes a reporting exercise the moment its measures only describe activity. The Realization Rate is realized value divided by earned value, which states plainly how much of what the enterprise earned reached a patient on sustained therapy. Customer Value at Risk is earned value multiplied by one minus that rate. The second number is the first one expressed in money, and finance conversations tend to move faster once it appears.

The distance between earned value and realized value is value leakage, and no competitor collects it. Work I published with TheyDo illustrated how the shortfall compounds. A billion dollars of earned value becomes roughly seven hundred million once prescriptions that are never filled are subtracted. Early discontinuation takes more, and long term adherence erosion leaves close to four hundred and fifty million in realized value.

That ladder is an illustrative compounded scenario rather than a benchmark, and the thresholds belong to each organization. The useful part is the shape. Losses of that kind accumulate quietly, acquire no owner and appear in no variance report, which is largely why they survive year after year.

Where the category is heading

The three established domains will keep earning their budgets, and they should. What changes is the question the function is asked to answer. Commercial excellence defined as the creation of intent has four decades of refinement behind it. Commercial excellence defined as the realization of value is a different job with a different measure, and most organizations have not yet decided which one they are running.

Deciding is cheaper than drifting. A function that names the fourth domain, assigns it an owner and gives it a measure can begin reporting a Realization Rate inside a single planning cycle. A function that leaves the domain unnamed will keep paying for recovery through hub services, field escalations and the goodwill of colleagues who refuse to let a patient fall through a seam. That spending is already happening, largely without governance and almost always without credit.

Key Takeaways

Commercial excellence in pharma has four domains rather than three. Launch, marketing and sales excellence are named and mature, while Customer Excellence is the fourth and the one now being named.
Each established domain deserves to be understood on its own terms. Launch excellence owns the first window, marketing excellence owns understanding, and sales excellence owns presence in the clinical community.
All three create clinical intent and none governs whether it survives. That shared boundary is a design gap rather than a shortcoming in any of the three disciplines.
Five markers separate a real function from a reporting one. A named discipline, an owner, a measure, a body of practice and a budget line are all required, since anything short of five is an initiative.
The function needs measures that describe realization rather than activity. The Realization Rate and Customer Value at Risk put experience into terms a finance conversation already accepts.
Value leakage is spending that happens whether or not it is governed. Recovery work is already funded informally through hub services, escalations and the discretionary effort of colleagues.

Diagnostic Questions to Consider

Name the four domains your commercial excellence function actually covers today, and identify which of them has no owner.
Test the function against the five markers, and state which markers are missing rather than which are present.
State the current Realization Rate for the lead brand, without estimating the figure in the room.
Calculate Customer Value at Risk for that brand and set it beside next year's promotional investment.
Identify where recovery work is already being funded informally, and determine what that effort would cost if it appeared on a budget line.

Closing Reflection

Four decades of commercial refinement in pharma produced three genuinely excellent disciplines. Every one of them earned its place, and the industry would be poorer without any of them. What they share is a boundary nobody drew deliberately, which is the point at which a prescribing decision passes out of the commercial organization's field of view.

I have come to read that boundary as an artifact of sequence rather than of judgment. The domains were built in the order the problems presented themselves, and the problem of realization presented itself last, after the vocabulary was already settled. Work that arrives after the vocabulary tends to go unnamed, and unnamed work rarely acquires an owner or a measure.

Commercial excellence is now being asked a harder question than the one it was designed to answer. Not how much intent the system can create, but how much of that intent reaches a patient and stays with them. The organizations that take the question seriously will spend a few years looking slower than their peers, because governance work rarely photographs as well as campaign work. The science they carry deserves a commercial system built to finish what it starts.

About the Author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

< Older Post

Newer Post >

[PRACTICE NOTE] Your Call Plan Isn’t the Problem. Your Customer Context Is.

March 15, 2026

Why healthcare professionals now judge pharmaceutical engagement against the best experiences in their lives, and what that means for the future of commercial leadership. When commercial performance falters, the reflex inside many pharmaceutical organizations is to adjust the machinery of field execution. Leaders revisit call plans, recalibrate targeting models, and increase the volume of activity in the hope that more precision or more frequency will restore momentum. For decades this system has been treated as the central instrument of commercial performance, determining which physicians are prioritized, how frequently representatives engage, and how resources are deployed across territories. Yet the growing gap between commercial effort and commercial impact suggests a deeper issue. T he problem is rarely the design of the call plan itself. It is the context in which healthcare professionals now operate. Physicians are navigating increasingly complex clinical, administrative, and informational environments, and that evolving reality now shapes prescribing behavior far more than the cadence of promotional interactions. What many organizations are experiencing is a widening Customer Context Gap. Commercial systems were designed for a time when prescribing decisions could be influenced primarily through promotional interaction and product information. Today physicians operate inside a far more complex reality shaped by administrative burden, reimbursement constraints, digital information overload, and growing expectations for seamless support across the entire care journey. In this environment the physician’s decision is influenced not only by clinical evidence but also by how easily a therapy fits into the practical realities of care delivery. When commercial models remain anchored in promotional activity while the customer’s context has fundamentally changed, even the most disciplined call plan struggles to deliver the outcomes it was designed to produce. Closing this gap requires a different way of thinking about commercial performance. The question is no longer how to optimize promotional activity but how to align the organization around the real journeys through which physicians help patients receive therapy. Prescribing decisions unfold within complex sequences of clinical evaluation, reimbursement navigation, patient readiness, and ongoing support. When commercial strategy is designed around these journeys rather than isolated interactions, the role of the field force begins to evolve. Representatives are no longer positioned primarily as messengers of information but as partners in removing barriers that slow care. Organizations that recognize this shift begin redesigning their commercial systems accordingly, aligning field engagement, digital support, access programs, and patient services around the same goal: helping healthcare professionals help patients move from clinical intent to successful treatment. From Promotional Activity to Customer Journeys The pharmaceutical industry has historically organized commercial activity around the moment of promotion. Call plans, targeting models, and message sequencing were designed to influence prescribing behavior primarily through informational engagement with healthcare professionals. While this model brought structure and scale to commercial operations, it reflects an earlier era in which the path from clinical awareness to prescribing action was comparatively linear. Today the journey is far more complex. Physicians must navigate an intricate landscape of clinical evidence, treatment guidelines, payer requirements, prior authorization processes, patient affordability concerns, and adherence challenges. Prescribing a therapy is no longer a single decision point. It is the beginning of a chain of events that determines whether a patient ultimately receives and remains on treatment. This is why the commercial conversation must expand beyond the traditional moment of prescription to encompass three interconnected journeys. The first is the Path-to-Prescribe , where scientific evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. The second is the Path-to-Fulfill, where access, affordability, patient readiness, and operational support determine whether that recommendation ultimately becomes therapy in the patient’s hands. The third is the Path-to-Adhere , where ongoing patient support, monitoring, and engagement determine whether patients remain on therapy long enough to realize the intended clinical benefit. Science drives the Path to Prescribe, where evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. Experience shapes the Path to Fulfill, where access, affordability, and patient readiness determine whether that recommendation becomes therapy in the patient’s hands. Sustained outcomes depend on the Path to Adhere, where ongoing support, monitoring, and engagement ensure patients remain on therapy long enough to realize its intended clinical benefit. When commercial organizations focus almost exclusively on the first while leaving the latter journeys fragmented and burdened, a significant portion of therapeutic value is lost between intention and impact. In many therapeutic areas, the result appears in the persistent gap between prescriptions written, prescriptions filled, and therapies sustained—gaps that reflect not a failure of science but a failure of system design. Recognizing these three journeys shifts the unit of focus from promotional activity to the real-world pathways through which care is delivered. It reframes the role of the field force, the purpose of digital engagement, and the design of patient support programs around a single objective: reducing the friction that stands between clinical intent, treatment initiation, and sustained patient outcomes. Customer Context Is the New Commercial Variable For much of the pharmaceutical industry’s history, commercial performance was largely explained by a familiar set of variables. Product efficacy, clinical differentiation, promotional reach, and sales force execution determined the trajectory of most brands. When performance lagged, leaders adjusted those levers by refining segmentation, optimizing targeting, and recalibrating call plans. Today those traditional levers still matter, but they no longer explain commercial outcomes on their own. A far more powerful variable has entered the equation: customer context. HCPs now operate within an environment defined not only by clinical complexity and administrative burden but also by rising expectations shaped by their experiences outside healthcare. Physicians are also consumers. In their personal lives they interact daily with companies such as Apple, Amazon, Tesla, and Netflix that anticipate their needs, remove friction, and simplify complex processes through thoughtful design. These experiences quietly reset the benchmark for competence, responsiveness, and respect for their time. When those same physicians step into their clinical roles, they do not shed those expectations. They carry them with them. The contrast between the seamless orchestration of their consumer experiences and the fragmented systems surrounding many healthcare interactions becomes difficult to ignore. What once felt acceptable now feels unnecessarily burdensome. This dynamic represents the Consumer-Grade Imperative. Healthcare professionals increasingly evaluate pharmaceutical engagement not against other pharmaceutical companies but against the best experiences they encounter anywhere in their lives. In this environment even a clinically superior therapy can struggle if the surrounding system makes it difficult to initiate treatment, navigate reimbursement, or support patient adherence. Customer context therefore becomes the new commercial variable. It determines whether scientific differentiation translates into practical adoption. It shapes whether prescribing intent becomes therapy initiation and whether therapy initiation becomes sustained patient outcomes. Call plans were designed to manage activity. Customer context requires organizations to manage journeys. The Field Force in the Era of Customer Context Recognizing customer context as the defining commercial variable inevitably reshapes how the role of the field force is understood. For decades the pharmaceutical sales representative has been positioned primarily as the carrier of scientific information. Call plans optimized the frequency and sequencing of these interactions to ensure that physicians received consistent messaging. That role does not disappear, but the environment surrounding it has changed profoundly. Physicians today are navigating administrative burden, payer complexity, digital information overload, and increasing time pressure. In this environment they are not simply seeking more information. They are seeking clarity, simplicity, and support that helps them navigate the complexity surrounding treatment decisions. This shift transforms the representative from a messenger of information into something far more valuable: a partner in removing friction from the care journey. Conversations move beyond repeating clinical claims toward understanding the practical barriers that physicians and their teams face as they attempt to initiate and sustain therapy for patients. The most effective field forces are therefore supported by commercial systems designed around journeys rather than activities. Representatives are equipped not only with scientific messaging but with the insight and coordination required to address obstacles across prescribing, reimbursement, and patient support. Field engagement becomes a catalyst for problem solving rather than simply a vehicle for promotion. From Call Plans to Customer-Aligned Commercial Systems If customer context has become the defining commercial variable, then the systems designed to support the field must evolve accordingly. The traditional call plan was built to manage activity. It provided structure for how frequently physicians were engaged, how territories were covered, and how resources were deployed. Yet activity alone does not determine whether therapies ultimately reach patients. What determines impact is whether the commercial system surrounding the physician reduces or increases the burden of delivering care. A customer-aligned commercial system begins with the journeys through which physicians help patients move from diagnosis to treatment and beyond. Marketing clarifies the scientific story. Sales provides trusted relationships and real-time understanding of physician needs. Access teams simplify reimbursement pathways. Patient support programs reduce administrative burden. Digital engagement reinforces and extends human interaction. The result is a commercial system that operates less like disconnected functions and more like an integrated network designed to help physicians help patients. This is the essence of Customer Excellence. It aligns the entire commercial enterprise around the real-world context in which care is delivered. The problem was never the call plan. The problem was the context. Key Takeaways Commercial performance in pharma organizations has traditionally been managed through field execution mechanics, yet the effectiveness of those mechanics increasingly depends on how well they reflect the real-world context in which physicians operate. Customer context has become the most pivotal commercial variable as administrative burden, payer complexity, and consumer-grade expectations reshape how prescribing decisions are made. HCPs now evaluate pharmaceutical engagement against the best experiences they encounter anywhere in their lives, raising the standard for clarity, responsiveness, and ease. Optimizing promotional activity alone is no longer sufficient. Commercial success depends on reducing friction across the journeys physicians navigate as they move patients from diagnosis to treatment. Customer Excellence represents the structural response, aligning marketing, sales, access, digital engagement, and patient support around the real journeys of care delivery . Diagnostic Questions to Consider Are we optimizing the activity of our field force, or designing commercial systems that support the real journeys physicians navigate to help patients receive therapy? How well do we understand the administrative, reimbursement, and operational barriers physicians encounter after they decide to prescribe a therapy? Do our commercial systems reduce the burden placed on physicians and their staff , or unintentionally add to the complexity of care delivery? Are we benchmarking our engagement against other pharma companies , or against the best experiences physicians encounter in their lives as consumers? Have our investments in digital platforms simplified the physician’s experience, or multiplied the number of disconnected interactions they must manage? Are we still managing performance through activity metrics alone , or beginning to understand the context that ultimately determines whether therapies reach patients? Closing Reflection The pharma and life sciences industry has spent decades refining the mechanics of field execution. Call plans, segmentation models, and targeting systems brought structure and discipline to commercial organizations. Yet the environment surrounding physicians has evolved far more rapidly than the systems built to support them. Healthcare professionals now operate in a world defined by consumer-grade expectations for clarity, responsiveness, and ease. When the experience of engaging with a pharmaceutical company fails to reflect those expectations, the contrast becomes impossible to ignore. Organizations that recognize this shift will redesign their commercial systems around the realities of modern care delivery. They will move beyond managing activity and toward understanding the context in which physicians help patients receive treatment. In doing so they will close the gap between scientific innovation and real-world impact. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a hands-on commercial excellence architect and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

Tan building with a hanging sign against a clear blue sky